ArticleEXCLI journal2018
Association between miR-124-1 rs531564 polymorphism and risk of cancer: An updated meta-analysis of case-control studies.
Article in EXCLI journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between genetic polymorphisms of long noncoding RNA H19 and cancer risk: a meta-analysis.Journal of genetics · 2019Pooled it
- Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis.Biomedicines · 2022Review
- A variant in microRNA-124 is involved in the control of neural cell apoptosis and associated with recovery after spinal cord injury (SCI).Archives of medical science : AMS · 2022Article
- Article
- The associations and roles of microRNA single-nucleotide polymorphisms in cervical cancer.International journal of medical sciences · 2021Review
- An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy.Frontiers in immunology · 2021Review
- The Relationship between Pre-miR-3131 3-bp Insertion/Deletion Polymorphism and Susceptibility and Clinicopathological Characteristics of Patients with Breast Cancer.MicroRNA (Shariqah, United Arab Emirates) · 2020Article
- Association of microRNA gene polymorphisms with Type 2 diabetes mellitus: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies examined the association between miR-124-1 rs531564 polymorphism and the risk of some human cancers, but the findings remain controversial. This update meta-analysis aimed to validate the association between rs531564 polymorphism of miR-124-1 and cancer risk. Eligible studies including 6,502 cancer cases and 7,213 controls were documented by searching Web of Science, PubMed, Scopus, and Google scholar databases. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated to quantitatively evaluate the association between rs531564 variant and cancer risk. The results indicated that rs531564 variant significantly decreased the risk of cancer in homozygous codominant (OR=0.54, 95 % CI=0.43-0.69, p<0.00001, GG vs CC), dominant (OR=0.84, 95 % CI=0.72-0.99, p=0.03, CG+GG vs CC), recessive (OR=0.65, 95 % CI=0.54-0.78, p<0.00001, GG vs CG+CC), and allele (OR=0.84, 95 % CI=0.73-0.96, p=0.008, G vs C) genetic model. Stratified analysis by cancer type revealed that rs531564 variant was associated with gastric cancer, cervical cancer, esophageal squamous cell carcinoma and colorectal cancer risk. In summary, the findings of this meta-analysis support an association between miR-124-1 rs531564 polymorphism and cancer risk. Larger and well-designed studies are required to estimate this association in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.